Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes

Published:2007-06-01 Issue:6 Volume:30 Page:1577-1578
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Makino Hirofumi¹,Haneda Masakazu²,Babazono Tetsuya³,Moriya Tatsumi⁴,Ito Sadayoshi⁵,Iwamoto Yasuhiko⁶,Kawamori Ryuzo⁷,Takeuchi Masahiro⁸,Katayama Shigehiro⁹,

Affiliation:

1. Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

2. Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical College, Hokkaido, Japan

3. Division of Nephrology and Hypertension, Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

4. Department of Endocrinology, Diabetes, and Metabolism, Kitasato University School of Medicine, Kanagawa, Japan

5. Division of Nephrology, Tohoku University Graduate Medical School, Miyagi, Japan

6. Department of Medicine, Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

7. Department of Medicine, Medical School, Juntendo University, Tokyo, Japan

8. Division of Biostatistics, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan

9. Division of Endocrinology and Diabetes, Department of Medicine, Saitama Medical School, Saitama, Japan

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/30/6/1577/597425/zdc00607001577.pdf

Reference8 articles.

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869, 2001

2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860, 2001

3. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878, 2001

4. Hollenberg NK: Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Curr Hypertens Rep 3:177, 2001

5. US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Available from http://www.usrds.org/adr_2005.htm

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?;BMC Nephrology;2024-01-25

2. Treatment and practical considerations of diabetic kidney disease;Frontiers in Medicine;2023-12-01

3. Synopsis of the Korean Society of Nephrology 2023 Practical Recommendations for the Management of Diabetic Kidney Disease;The Korean Journal of Medicine;2023-12-01

4. DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial;eClinicalMedicine;2023-12

5. Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study;Scientific Reports;2023-09-29